These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34234256)
1. Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma. Schwinn S; Mokhtari Z; Thusek S; Schneider T; Sirén AL; Tiemeyer N; Caruana I; Miele E; Schlegel PG; Beilhack A; Wölfl M Sci Rep; 2021 Jul; 11(1):14062. PubMed ID: 34234256 [TBL] [Abstract][Full Text] [Related]
2. The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma. Ehrhardt M; Craveiro RB; Velz J; Olschewski M; Casati A; Schönberger S; Pietsch T; Dilloo D J Cell Mol Med; 2018 Apr; 22(4):2153-2161. PubMed ID: 29377550 [TBL] [Abstract][Full Text] [Related]
3. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544 [TBL] [Abstract][Full Text] [Related]
4. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106 [TBL] [Abstract][Full Text] [Related]
5. TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI. Komar-Stossel C; Gross E; Dery E; Corchia N; Meir K; Fried I; Abramovitch R PLoS One; 2014; 9(3):e90224. PubMed ID: 24603724 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296 [TBL] [Abstract][Full Text] [Related]
7. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137. Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769 [TBL] [Abstract][Full Text] [Related]
8. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741 [TBL] [Abstract][Full Text] [Related]
9. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413 [No Abstract] [Full Text] [Related]
10. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843 [TBL] [Abstract][Full Text] [Related]
11. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813 [TBL] [Abstract][Full Text] [Related]
12. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120 [TBL] [Abstract][Full Text] [Related]
14. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591 [TBL] [Abstract][Full Text] [Related]
15. Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts. Hori Y; Ito K; Hamamichi S; Ozawa Y; Matsui J; Umeda IO; Fujii H Anticancer Res; 2017 Dec; 37(12):6629-6638. PubMed ID: 29187438 [TBL] [Abstract][Full Text] [Related]
16. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Zhang Y; Schwerbrock NM; Rogers AB; Kim WY; Huang L Mol Ther; 2013 Aug; 21(8):1559-69. PubMed ID: 23774791 [TBL] [Abstract][Full Text] [Related]
17. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. Rodriguez-Blanco J; Salvador AD; Suter RK; Swiderska-Syn M; Palomo-Caturla I; Kliebe V; Shahani P; Peterson K; Turos-Cabal M; Vieira ME; Wynn DT; Howell AJ; Yang F; Ban Y; McCrea HJ; Zindy F; Danis E; Vibhakar R; Jermakowicz A; Martin V; Coss CC; Harris BT; de Cubas A; Chen XS; Barnoud T; Roussel MF; Ayad NG; Robbins DJ J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38885332 [TBL] [Abstract][Full Text] [Related]
18. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100 [TBL] [Abstract][Full Text] [Related]
19. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447 [TBL] [Abstract][Full Text] [Related]
20. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Shu Q; Antalffy B; Su JM; Adesina A; Ou CN; Pietsch T; Blaney SM; Lau CC; Li XN Clin Cancer Res; 2006 Aug; 12(15):4687-94. PubMed ID: 16899619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]